Akebia Therapeutics (AKBA) Total Debt Growth (3y) (2021 - 2026)
Akebia Therapeutics (AKBA) Total Debt Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | 15.43% |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -7.08% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 11.33% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -3.67% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -10.43% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -13.72% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 92.83% |
| 10 | Akebia Therapeutics | 244.72 Mn | 89.17 Mn | 38.70 Mn | 20.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.52% |
| Mar 31, 2026 | -0.94% |
| Dec 31, 2025 | -9.95% |
| Sep 30, 2025 | -28.78% |
| Jun 30, 2025 | -37.88% |
| Mar 31, 2025 | -21.96% |
| Dec 31, 2024 | -26.52% |
| Sep 30, 2024 | -26.66% |
| Jun 30, 2024 | -26.79% |
| Mar 31, 2024 | -32.17% |
| Dec 31, 2023 | -28.87% |
| Sep 30, 2023 | -17.76% |
| Jun 30, 2023 | -17.74% |
| Mar 31, 2023 | -12.88% |
| Dec 31, 2022 | -4.47% |
| Dec 31, 2021 | 86.65% |